Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Gianluca Pettiti, listed as Executive Vice President of Thermo Fisher Scientific (TMO), reported multiple dispositions of Common Stock on 08/28/2025. Four separate line items show sales (transaction code F) totaling 814.702 shares at $489.74 per share, with post-transaction beneficial ownership reported as 21,552.223 to 22,167.238 shares across the entries. The Form 4 is signed by an attorney-in-fact on 09/02/2025. The filing provides name, address, role, transaction dates, codes, quantities, price, and resulting ownership figures.
Thermo Fisher Scientific insider transaction: This Form 4 shows Lisa P. Britt, Sr. VP and Chief HR Officer, reported four dispositions of Thermo Fisher common stock on 08/28/2025. Each line records a transaction code "F" disposing of 81.229, 87.514, 96.7, and 63.339 shares at $489.74 per share. The reported beneficially owned share totals after each disposition are 16,142.357, 16,054.843, 15,958.143, and 15,894.804 shares, respectively. The form is signed by an attorney-in-fact on behalf of Ms. Britt on 09/02/2025. The filing is a routine Section 16 disclosure documenting insider sales; no derivative transactions or additional explanatory text are provided.
Thermo Fisher Scientific Inc. has completed its acquisition of Solventum Corporation’s purification and filtration business. The company announced the closing in a press release dated September 2, 2025, following the earliest event date of September 1, 2025.
The acquired operations focus on purification and filtration technologies, which fit within Thermo Fisher’s broader scientific and laboratory solutions portfolio. Details such as purchase price, financing, and expected financial impact are not included in this summary document but are referenced in the attached press release.
Thermo Fisher Scientific (TMO) Form 144 notice for a proposed sale of common stock. The filing shows 385 shares to be sold through Fidelity Brokerage Services with an approximate aggregate market value of $189,661.91 and an approximate sale date of 08/29/2025 on the NYSE. The filing reports 377,612,121 shares outstanding. The securities were listed as acquired on 08/29/2025 by exercise of an option granted 02/26/2019, and payment is indicated as cash. Several identifying fields such as the filer CIK/CCC and the named person for whose account the securities are to be sold are blank in the provided text, and no sales in the past three months are reported.
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported option exercise and offsetting open-market sales executed under a 10b5-1 plan. He exercised a stock option to acquire 10,000 shares at an exercise price of $253.99 on 08/22/2025. On the same date he sold a total of 10,000 shares in multiple transactions at weighted-average prices within three reported ranges: approximately $500.00–$500.98, $501.05–$501.99, and $502.02–$502.37. Following these transactions his direct beneficial ownership is reported as 115,173.623 shares, and he also reports indirect holdings through trusts and entities totaling additional positions. The sales were made pursuant to a Rule 10b5-1 trading plan adopted April 28, 2025.
Form 144 notice for Thermo Fisher Scientific (TMO) shows a proposed sale of 10,000 common shares through Fidelity Brokerage Services with an aggregate market value of $5,009,587.68, and lists prior sales by the same seller during August 2025 totaling 18,496 shares for gross proceeds of $8,196,802.53. The filing states the 10,000 shares were acquired by option grant (original grant date 02/26/2019) and scheduled for sale and payment on 08/22/2025 for cash. The table lists the issuer’s outstanding shares as 377,612,121 and the planned execution on the NYSE. The filer certifies, by signing the notice, that they are not aware of undisclosed material adverse information and references Rule 10b5-1 procedures if applicable.
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported multiple transactions on Form 4. On 08/19/2025 and 08/20/2025 the filing shows purchases of common stock (totaling 496 shares) at $253.99 and contemporaneous sales of common stock (totaling 496 shares) at a weighted-average price near $500.17. Following the reported trades, the filing lists total beneficial ownership of common stock at approximately 115,173.623 shares (direct) plus several indirect holdings: 11,300, 14,608, and 5,000 shares via trusts or entities. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted April 28, 2025, and includes option-related entries showing acquisition of stock options with underlying shares of 201 and 295 that vest/exercisable per earlier vesting dates.
Form 144 notice for proposed sale of Thermo Fisher Scientific, Inc. (TMO) securities. The filer reports offering 295 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $147,512.35 and an approximate sale date of 08/20/2025. The filing lists 377,612,121 shares outstanding. The securities to be sold were acquired on 08/20/2025 by exercise of an option originally granted on 02/26/2019, and the payment method is indicated as cash. The filing also discloses securities sold during the past three months by Marc N. Casper totaling 18,201 shares for aggregate gross proceeds of $8,254,290.17. The notice includes the standard representation that the seller does not possess undisclosed material adverse information and contains the routine attestations required by Rule 144.
Thermo Fisher Scientific (TMO) Rule 144 notice shows an insider proposes to sell 201 shares of common stock through Fidelity Brokerage, with an aggregate market value of $100,533.57 based on the filing. The shares are reported as acquired via an option granted on 02/26/2019 and exercised/dated 08/19/2025 with cash payment. The filer has aggregated recent dispositions: Marc N. Casper sold 10,000 shares on 08/06/2025 for $4,518,207.00 and 8,000 shares on 08/07/2025 for $3,635,549.60. The notice includes the standard insider representation that no material nonpublic information is known.
Form 144 notice for Thermo Fisher Scientific, Inc. (TMO): An owner proposes to sell 11,440 common shares through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/19/2025. The filing reports an aggregate market value of $5,671,128.27 and a total of 377,612,121 shares outstanding, and indicates the shares were acquired under an option granted on 09/09/2020 with the acquisition dated 08/19/2025. Payment for the sale is listed as cash. The filer certifies they are not aware of any undisclosed material adverse information and notes there were no sales in the past three months by the same person.